13 November 2018

Contents

Editorial

• 13 November 2018: vol 19 no 17: HIVR4P and Glasgow conferences: first reports

Conference reports

• Glasgow HIV Congress (2018)

• No additional neural tube defects with preconception dolutegravir: data from three birth outcome cohorts

• Insufficient data on risk of neural tube defects with exposure to elvitegravir or bictegravir exposure during preconception or first trimester

• Viral dynamics of dolutegravir-based dual versus triple ART

• Ibalizumab: 48-week phase 3 results in 27 participants with MDR HIV

• Fostemsavir: 48-week phase 3 results from BRIGHTE study

• Dolutegravir non-inferior to low dose efavirenz in real-life African study conducted in Cameroon  

• 3rd HIV Research for Prevention Conference (R4P2018)

• How to evaluate PrEP and vaccines: urgency for next generation compounds

• Dual bNAb maintains viral suppression for median 21 weeks off-ART

• Cabotegravir levels can be detected several years: PK tail to be covered by oral PrEP

• 3D imaging show HIV infection might establish within hours

• bNAbs for HIV prevention: extended-release VRC01, AMP study, 10E8 safety signal and pan-clade challenges

• Why U=U does not cover breastfeeding

Antiretrovirals

• FDA updates rilpivirine label for use during pregnancy

Treatment access

• Activists demand $1 a day access to bedaquiline for MDR TB

Guidelines

• EACS guidelines – version 9.1 update (2018)

Side effects

• Cannabis-based products for medicinal use: Guidance to clinicians

PDFs

• 13 November 2018: vol 19 no 17